GLP3-R (Retatrutide)

Overview

Retatrutide (LY3437943), listed as GLP3-R in the research community, is a next-generation triple-agonist peptide that simultaneously targets GIP, GLP-1, and glucagon receptors. This three-pronged mechanism distinguishes it from earlier single- and dual-agonist compounds, making it one of the most closely watched research peptides in the metabolic space.

Mechanism of Action

Retatrutide activates three distinct receptor pathways. GLP-1 receptor activation slows gastric emptying and promotes satiety signaling in the hypothalamus. GIP receptor engagement enhances insulin sensitivity and supports lipid metabolism. Glucagon receptor activation drives hepatic fat oxidation and increases energy expenditure. The combined effect of all three pathways produces a synergistic metabolic response that exceeds what any single pathway achieves alone.

Research Context

Clinical trial data has shown significant body weight reduction in study participants over 48-week periods. Researchers have observed dose-dependent effects across multiple metabolic markers including HbA1c, fasting glucose, and triglyceride levels. The glucagon component is of particular interest because it adds a thermogenic and lipolytic dimension absent from GLP-1-only compounds.

Key Research Areas

Considerations for Researchers

Retatrutide requires proper cold-chain storage at 2-8C before reconstitution. Reconstituted solutions should be refrigerated and used within a defined stability window. Researchers should verify peptide identity and purity via third-party LC-MS/HPLC testing before use in any protocol.